Prelude Therapeutics, Inc. (PRLD)
1.70
+0.24
(+16.44%)
USD |
NASDAQ |
Dec 09, 16:00
1.66
-0.04
(-2.35%)
After-Hours: 20:00
Prelude Therapeutics Shareholders Equity (Quarterly): 58.53M for Sept. 30, 2025
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Incyte Corp. | 4.651B |
| Nautilus Biotechnology, Inc. | 169.14M |
| Protalix Biotherapeutics, Inc. | 52.91M |
| ALX Oncology Holdings, Inc. | 44.80M |
| Erasca, Inc. | 347.89M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 94.76M |
| Total Liabilities (Quarterly) | 36.22M |
| Debt to Equity Ratio | 0.305 |
| Current Ratio | 3.207 |
| Net Debt Paydown Yield | 0.09% |